Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD 6244

Known as: AZD-6244, AZD6244, MEK inhibitor AZD6244 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
BACKGROUND Effective medical therapies are lacking for the treatment of neurofibromatosis type 1-related plexiform neurofibromas… Expand
  • table 1
  • table 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Targeted therapies have demonstrated efficacy against specific subsets of molecularly defined cancers. Although most patients… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
UNLABELLED PARP inhibitors are active in tumors with defects in DNA homologous recombination (HR) due to BRCA1/2 mutations. The… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
It has been proposed that an aggressive secondary cancer stem cell population arises from a primary cancer stem cell population… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
SummarySelumetinib is a potent, selective MEK inhibitor with efficacy in several tumor models. This study compared selumetinib… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Amplification of an upstream gene leads to resistance to cancer drugs targeted downstream. Making Resistance Futile One of the… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Genetic alterations that activate the mitogen-activated protein kinase (MAP kinase) pathway occur commonly in cancer. For example… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Purpose: The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Constitutive activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) mitogen-activated protein kinase (MAPK… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?